Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
Authors
Linong Ji (ORCID: https://orcid.org/0000-0003-1305-1598)
Pangke Yan (ORCID: https://orcid.org/0009-0006-0626-4148)
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
Linong Ji, Pangke Yan, Leili Gao, Hongwei� Jiang et al.
Citations
5 citations
Journal
Diabetes Obesity and Metabolism
Topics
Diabetes Treatment and Management
Field-Weighted Citation Impact (FWCI)
1.79
article
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
Linong Ji, Pangke Yan, Leili Gao, Hongwei� Jiang, Jia Sun, Jianzhong Xiao, Chengxia Jiang, Bo Feng, Fang Bian, Tianrong Pan
article en
5 citations
Abstract
No abstract available for this paper.
Publication Tag
Diabetes Obesity and MetabolismVol. 27(1)
Institutions
Anhui Medical University (CN), Peking University (CN), China National Pharmaceutical Group Corporation (China) (CN), People's Hospital of Cangzhou (CN), Zhujiang Hospital (CN), Peking University People's Hospital (CN), Shanghai East Hospital (CN), First Affiliated Hospital of Henan University of Science and Technology (CN), Second Affiliated Hospital of Anhui Medical University (CN), Beijing Tsinghua Chang Gung Hospital (CN), Second People’s Hospital of Yibin (CN), Southern Medical University (CN)